EuroBiotech: More Articles of Note

newspapers
(Pixabay)

> Pharming began a phase 1/2 trial of its recombinant human C1 esterase inhibitor in patients with pre-eclampsia. The trial is scheduled to deliver data in the third quarter of 2020. Release 

> Oncurious received a grant from Flanders Innovation and Entrepreneurship to support preclinical development of its cancer immunotherapies. The Belgian biotech hopes to identify and test multispecific biologics. Statement 

> Galapagos and Servier completed enrollment in a phase 2 osteoarthritis trial. The trial is assessing the effect of 52 weeks of treatment with ADAMTS-5 inhibitor GLPG1972. Release 

FREE DAILY NEWSLETTER

Like this story? Subscribe to FierceBiotech!

Biopharma is a fast-growing world where big ideas come along every day. Our subscribers rely on FierceBiotech as their must-read source for the latest news, analysis and data in the world of biotech and pharma R&D. Sign up today to get biotech news and updates delivered to your inbox and read on the go.

> A phase 2b trial of NeRRe Therapeutics’ orvepitant missed its primary endpoint. The neurokinin-1 receptor antagonist was no better than placebo at reducing awake cough frequency in refractory chronic cough. Statement 

> Pfizer picked a clinical candidate from its collaboration with Sosei Heptares, triggering a $3 million (€2.7 million) milestone payment. The candidate is the second picked by Pfizer in as many months. Release

> Immunicum posted phase 1/2 data on its lead candidate in gastrointestinal stromal tumors. Release

Suggested Articles

AbbVie snagged the option to license Harpoon’s anti-BCMA multiple myeloma candidate and the duo added up to six new targets to their discovery deal.

In this week's EuroBiotech Report, Bayer's heart failure drug clears phase 3 test, ABPI calls for more U.K. investment and GHO raises €975 million. 

In our EuroBiotech roundup this week, Azeria raises £32 million, Zealand delays phase 3 readout and Galapagos eyes early 2021 IPF futility analysis.